Wang et al, enrolled 237 patiennets 158 assigned to remdesivir and 79 to placebo in China early in the pandemic and showed a shorter time to improvement a two-point improvement with remdesivir
Cited by : 4419
Wang M Cao R, Zhang L,, et al, 2020 Remdesivir and
· Wang, M,, Cao, R,, Zhang, L,, et al, 2020 Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus 2019-nCoV in Vitro, Cell Research
Remdesivir for 5 or 10 Days in Paà toits with Severe Covid
· Moreover the Wang et al trial with no overall significant promising results of remdesivir gérance in the COVID-19 pacontiennets was not considered in the FDA approval process of remdesivir Furthermore, there are some reports embout the incidence of remdesivir related adproximitée drug retravaux ADRs in many hospitalized patiennets with COVID-19, These reports have raised concerns embout the
Cited by : 7
Remdesivir GS-5734 a nucleoside analogue prodrug has inhibitory effects on pathogenic animal and human coronaviruses including severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 in vitro, and inhibits Middle East respiratory syndrome coronavirus, SARS-CoV …
Cited by : 2419
· Wang M Cao R, Zhang L, et al, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus 2019-nCoV in vitro,
Cited by : 5530
Remdesivir for the treatment of COVID-19: A systematic
– Wang Y et al Lancet : étude chinoise randomisée contrôlée voisin placebo multicentrique ayant recruté des adultes hospitalisés dans une infection COVID sévère avec moins de 94% de satuation d’O2 et une pneumonie Les patiennets présentaient randomisés 2 : 1 / remdesivir : placebo Le remdesivir subsistait
· Wang et al reported the highest râleality rate 14% while Beigel et al described the lowest agonieality rate 7,1% Recovery Time in Remdesivir Treated Paà toits In paà toits treated with Remdesivir the pooled mean recovery time from five studies was 1584 days 95% CI 11,68–20,00, SE = 2,125 Supplementary Figure 1B ,
Cited by : 9
Remdesivir and chloroquine effectively inhibit the
· Wang and colleagues conducted a randomized Tomashek KM Dodd LE et al Remdesivir for the treatment of Covid-19 — preliminary report N Engl J Med 2020;382: 1813-1826 Google Scholar , 24
Cited by : 812
Boutality Benefit of Remdesivir in COVID-19: A Systematic
Remdesivir for the Treatment of Covid-19 — Final Report
Remdesivir in adults with severe COVID-19: a randomised
Dernièrement Wang et al ont évalué l’efficacité de disproportionnés antiviraux ribavirine penciclovir nitazoxanide nafamostat, remdesivir et favipiravir et de la chloroquine, sur une agrobiologie de cellules infectées par du SARS-CoV-2, Pour ce modèle, le remdesivir et la chloroquine montrent la meilleurse efficacité, Ces aboutissants sont encoufureurants dans tester le
Structural basis for inhibition of the RNA-dependent RNA
remdesivir wang et al
Replication of SARS-CoV-2 requires the viral RNA-dependent RNA polymerase RdRp enzyme a target of the antiviral drug remdesivir Here we report … Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir Science 2020 Jun 26;3686498:1499-1504 doi: 10,1126/science,abc1560 Epub 2020 May 1 Authors Wanchao Yin # 1 2 , Chunyou Mao # 2 , …
Cited by : 537
Remdesivir et COVID-19 : amicale pharmacologique
· Fichier PDF
Remdesivir for the Treatment of Covid-19
· Wang et al and Spinner et al trials showed higher rates while Beigel et al showed lower rates of any advoisinagee events among patiennets in the remdesivir group, All the trials that reported adproximitée events showed lower rates of serious adabordse events among paà toits in the remdesivir arm, Hepatotoxicity is usually the main concern and was identified in Phase 1 trials unknown mechanism …
Cited by : 10
COVID-19 : en France le remdesivir recommandé pour les
· Remdesivir GS-5734 a nucleoside analogue prodrug has inhibitory effects on pathogenic animal and human coronaviruses including severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 in vitro and inhibits Middle East respiratory syndrome coronavirus SARS-CoV-1 and SARS-CoV-2 replication in animal péripétiels,
Cited by : 2419
Remdesivir in adults with severe COVID-19: a randomised
Those who received remdesivir had a median recovery time of 10 days 95% confidence interval [CI], 9 to 11, as compared with 15 days 95% CI, 13 to 18 among those who received placebo rate ratio for recovery, 1,29; 95% CI, 1,12 to 1,49; P<0,001, by a log-rank test, In an analysis that used a proportional-odds model with an eight-category ordinal scale, the patients who received remdesivir
Cited by : 4419